Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Study Phase : Discovery Platform
Sponsor : Revolution Medicines
Deal Size : $25.0 million
Deal Type : Collaboration
Revolution & Iambic Announces Collaboration to Pursue New Drug Candidates
Details : Through the collaboration Iambic will use structures and molecular libraries provided by Revolution Medicines to pursue novel drug candidates using Iambic’s leading AI models.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Undisclosed
July 09, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Highest Development Status : Discovery Platform
Sponsor : Revolution Medicines
Deal Size : $25.0 million
Deal Type : Collaboration
Lead Product(s) : IAM1363,Trastuzumab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Mubadala Capital
Deal Size : $150.0 million
Deal Type : Series B Financing
Iambic Closes $50M Series B Extension to Broaden AI-Discovered Oncology Programs
Details : The proceeds from the financing will be used to advance the IAM1363, a highly selective, brain-penetrant small molecule inhibitor, being evaluated for the treatment of HER2-mutated neoplasms.
Product Name : IAM1363
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 18, 2024
Lead Product(s) : IAM1363,Trastuzumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Mubadala Capital
Deal Size : $150.0 million
Deal Type : Series B Financing
Lead Product(s) : IAM1363
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Iambic Therapeutics To Present Data for IAM1363 At AACR Annual Meeting
Details : IAM1363 inhibits both wild type and mutant HER2 forms, showing over 1000-fold selectivity against EGFR, being evaluated for HER2-driven cancers.
Product Name : IAM1363
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 28, 2024
Lead Product(s) : IAM1363
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : IAM-H1
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Ascenta Capital
Deal Size : $100.0 million
Deal Type : Series B Financing
Details : The financing will advance multiple candidates into clinical development, expand its pipeline with best-in-class and first-in-class potential, including IAM-H1, a Selective Brain-Penetrant HER2 Inhibitor, and IAM-C1, a Selective Dual CDK2/4 Inhibitor.
Product Name : IAM-H1
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 10, 2023
Lead Product(s) : IAM-H1
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Ascenta Capital
Deal Size : $100.0 million
Deal Type : Series B Financing